Quoin Pharmaceuticals Appoints Gordon Dunn as Chief Financial Officer

 

Source:  Quoin Pharmaceuticals, Inc. 11/4/2021

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has appointed Gordon Dunn as Quoin’s Chief Financial Officer, effective immediately.

Mr. Dunn has over 30 years of finance experience. He has served as CFO of both private and publicly traded companies and has deep experience in investment banking and private equity as well. During the past five years he has served as Chief Financial Officer for several private companies, most recently with Qured, a UK-based healthcare provider, from 2020 to 2021. Mr. Dunn also served as CFO of Innocoll AG. from 2012-2016.

Dr. Michael Myers, Chief Executive Officer of Quoin, commented, “Gordon Dunn has the right experience to serve as Quoin’s Chief Financial Officer. His deep background with both public and private companies, and in investment banking and private equity, will support Quoin as we execute our strategic plans to build our company to develop and commercialize therapeutic products that treat rare and orphan diseases. We welcome Gordon to the Quoin team.”

“I’m excited to join Quoin at this important time in the Company’s evolution. I share in Quoin’s vision to address the unmet needs of patients and look forward to working with the team to achieve its goals,” added Gordon Dunn.

Prior to joining Innocoll, Mr. Dunn worked for over 20 years in the investment banking and private equity sector, including over ten years managing the private equity funds of NewSmith Capital, and nine years at Merrill Lynch, where he served as co-head of the European Private Equity Group and Director of Equity Capital Markets. Mr. Dunn received a B.A. from Stanford University and a J.D. from the New York University School of Law.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises three products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others. For more information, go to: www.quoinpharma.com.